These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 23029050

  • 21. Upregulation of Death Receptor 5 and Production of Reactive Oxygen Species Mediate Sensitization of PC-3 Prostate Cancer Cells to TRAIL Induced Apoptosis by Vitisin A.
    Shin D, Kwon HY, Sohn EJ, Nam MS, Kim JH, Lee JC, Ryu SY, Park B, Kim SH.
    Cell Physiol Biochem; 2015; 36(3):1151-62. PubMed ID: 26111475
    [Abstract] [Full Text] [Related]

  • 22. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
    Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, Röder C, Schütze S, Wajant H, Kalthoff H, Trauzold A.
    J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842
    [Abstract] [Full Text] [Related]

  • 23. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
    Sung ES, Park KJ, Choi HJ, Kim CH, Kim YS.
    Exp Cell Res; 2012 Aug 01; 318(13):1564-76. PubMed ID: 22513214
    [Abstract] [Full Text] [Related]

  • 24. Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity.
    Ding B, Wu X, Fan W, Wu Z, Gao J, Zhang W, Ma L, Xiang W, Zhu Q, Liu J, Ding X, Gao S.
    Int J Nanomedicine; 2011 Aug 01; 6():1991-2005. PubMed ID: 21976975
    [Abstract] [Full Text] [Related]

  • 25. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
    Zhang L, Zhang X, Barrisford GW, Olumi AF.
    Cancer Lett; 2007 Jun 18; 251(1):146-57. PubMed ID: 17184908
    [Abstract] [Full Text] [Related]

  • 26. Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells.
    Ahmed SM, Wu X, Jin X, Zhang X, Togo Y, Suzuki T, Li Y, Kanematsu A, Nojima M, Yamamoto S, Sugimoto M, Kakehi Y.
    Oncol Rep; 2015 Feb 18; 33(2):566-72. PubMed ID: 25483927
    [Abstract] [Full Text] [Related]

  • 27. Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.
    Du X, Xiang L, Mackall C, Pastan I.
    Clin Cancer Res; 2011 Sep 15; 17(18):5926-34. PubMed ID: 21813632
    [Abstract] [Full Text] [Related]

  • 28. Anticancer Effect of Ursodeoxycholic Acid in Human Oral Squamous Carcinoma HSC-3 Cells through the Caspases.
    Pang L, Zhao X, Liu W, Deng J, Tan X, Qiu L.
    Nutrients; 2015 May 05; 7(5):3200-18. PubMed ID: 25951128
    [Abstract] [Full Text] [Related]

  • 29. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
    Yang J, Li G, Zhang K.
    Biomed Pharmacother; 2016 Dec 05; 84():1078-1087. PubMed ID: 27780136
    [Abstract] [Full Text] [Related]

  • 30. The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells.
    Kauntz H, Bousserouel S, Gossé F, Raul F.
    Apoptosis; 2012 Aug 05; 17(8):797-809. PubMed ID: 22555452
    [Abstract] [Full Text] [Related]

  • 31. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.
    Surget S, Chiron D, Gomez-Bougie P, Descamps G, Ménoret E, Bataille R, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C.
    Cancer Res; 2012 Sep 01; 72(17):4562-73. PubMed ID: 22738917
    [Abstract] [Full Text] [Related]

  • 32. Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins.
    Shibuya H, Kato Y, Saito M, Isobe T, Tsuboi R, Koga M, Toyota H, Mizuguchi J.
    Melanoma Res; 2003 Oct 01; 13(5):457-64. PubMed ID: 14512787
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.
    Biochem Pharmacol; 2012 Mar 15; 83(6):769-77. PubMed ID: 22230479
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
    Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB.
    Apoptosis; 2006 Jul 15; 11(7):1175-93. PubMed ID: 16699949
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.